Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.21.2
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenue:        
Grant and contract revenue $ 501,567 $ 849,732 $ 1,499,706 $ 2,344,777
Operating expenses:        
Research and development 4,381,542 3,172,663 12,004,084 8,745,966
General and administrative 3,390,093 6,579,193 11,011,003 11,651,415
Change in fair value of contingent consideration 295,000 229,000 406,000 1,045,000
Total operating expenses 8,066,635 9,980,856 23,421,087 21,442,381
Loss from operations (7,565,068) (9,131,124) (21,921,381) (19,097,604)
Change in fair value of warrant liability 6,831 (37,230) 2,808 (1,039,303)
Investor relations expense       (66,767)
Interest income 195,344 140,614 567,307 249,404
Other (expense) income, net (185,332) 111,307 (440,675) 127,599
Total non-operating income (loss) 16,843 214,691 129,440 (729,067)
Net loss before income taxes (7,548,225) (8,916,433) (21,791,941) (19,826,671)
Net loss (7,548,225) (8,916,433) (21,791,941) (19,826,671)
Net loss - non-controlling interest (115,505) (64,824) (283,846) (228,526)
Net loss attributable to Heat Biologics, Inc. $ (7,432,720) $ (8,851,609) $ (21,508,095) $ (19,598,145)
Net loss per share, basic (in dollars per share) $ (0.30) $ (0.43) $ (0.87) $ (1.42)
Net loss per share, diluted (in dollars per share) $ (0.30) $ (0.43) $ (0.87) $ (1.42)
Weighted-average common shares outstanding, basic (in shares) 25,137,628 20,532,696 24,828,438 13,783,039
Weighted-average common shares outstanding, diluted (in shares) 25,137,628 20,532,696 24,828,438 13,783,039
Comprehensive loss:        
Net loss $ (7,548,225) $ (8,916,433) $ (21,791,941) $ (19,826,671)
Unrealized gain (loss) on foreign currency translation 68,582 (63,954) 113,511 (24,660)
Total comprehensive loss (7,479,643) (8,980,387) (21,678,430) (19,851,331)
Comprehensive loss attributable to non-controlling interest (115,505) (64,824) (283,846) (228,526)
Comprehensive loss - Heat Biologics, Inc. $ (7,364,138) $ (8,915,563) $ (21,394,584) $ (19,622,805)